Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Tue, Jul 7, 2026

1 updates

7:30 AM

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

cytokinetics.com

Wed, Jun 17, 2026

1 updates

4:00 PM

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

cytokinetics.com

Mon, Jun 8, 2026

1 updates

7:30 AM

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

cytokinetics.com

Mon, Jun 1, 2026

1 updates

7:30 AM

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

cytokinetics.com

Wed, May 27, 2026

1 updates

4:00 PM

Cytokinetics to Participate in June Investor Conferences

cytokinetics.com

Wed, May 20, 2026

1 updates

4:00 PM

Cytokinetics to Hold Annual Meeting of Stockholders

cytokinetics.com

Mon, May 18, 2026

1 updates

4:00 PM

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

cytokinetics.com

Thu, May 14, 2026

1 updates

7:30 AM

Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

cytokinetics.com

Tue, May 12, 2026

1 updates

4:00 PM

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

cytokinetics.com

Mon, May 11, 2026

1 updates

10:06 AM

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

cytokinetics.com

Fri, May 8, 2026

1 updates

10:51 AM

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million

cytokinetics.com

Wed, May 6, 2026

1 updates

11:00 PM

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

cytokinetics.com

Tue, May 5, 2026

3 updates

4:15 PM

Cytokinetics Announces Proposed Public Offering of Common Stock

cytokinetics.com

4:05 PM

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

cytokinetics.com

7:30 AM

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Trial Results • Phase 3cytokinetics.com

Mon, May 4, 2026

1 updates

4:00 PM

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

cytokinetics.com

Tue, Apr 28, 2026

1 updates

7:30 AM

Cytokinetics Announces Ten Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

cytokinetics.com

Tue, Apr 21, 2026

1 updates

4:00 PM

Cytokinetics to Announce First Quarter Results on May 5, 2026

cytokinetics.com

Mon, Apr 20, 2026

1 updates

4:00 PM

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

cytokinetics.com